SGLT2 inhibitors work in the kidney, blocking the transporter that reabsorbs glucose back into the blood — so excess sugar leaves in the urine. They began as diabetes drugs, but large trials found they also protect the heart and kidneys, cutting hospitalisation for heart failure even in people without diabetes. That has made them a cornerstone of cardiology and nephrology as much as of diabetes care.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons